N
128.39
0.35 (0.27%)
| Previous Close | 128.04 |
| Open | 127.88 |
| Volume | 810,218 |
| Avg. Volume (3M) | 1,053,864 |
| Market Cap | 12,733,913,088 |
| Price / Earnings (TTM) | 37.99 |
| Price / Earnings (Forward) | 25.77 |
| Price / Sales | 5.44 |
| Price / Book | 4.89 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | 12.68% |
| Operating Margin (TTM) | 4.14% |
| Diluted EPS (TTM) | 2.95 |
| Quarterly Revenue Growth (YOY) | 11.10% |
| Quarterly Earnings Growth (YOY) | -81.80% |
| Total Debt/Equity (MRQ) | 19.45% |
| Current Ratio (MRQ) | 3.13 |
| Operating Cash Flow (TTM) | 529.90 M |
| Levered Free Cash Flow (TTM) | 235.48 M |
| Return on Assets (TTM) | 8.75% |
| Return on Equity (TTM) | 12.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Neurocrine Biosciences, Inc. | Bullish | Bearish |
AIStockmoo Score
0.6
| Analyst Consensus | 4.0 |
| Insider Activity | -4.0 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.60 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
| % Held by Insiders | 1.06% |
| % Held by Institutions | 98.86% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 182.00 (Goldman Sachs, 41.76%) | Buy |
| Median | 168.50 (31.24%) | |
| Low | 141.00 (Wedbush, 9.82%) | Buy |
| Average | 163.10 (27.04%) | |
| Total | 9 Buy, 1 Hold | |
| Avg. Price @ Call | 129.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 01 Aug 2025 | 175.00 (36.30%) | Buy | 128.91 |
| JP Morgan | 31 Jul 2025 | 145.00 (12.94%) | Hold | 128.23 |
| Morgan Stanley | 31 Jul 2025 | 158.00 (23.06%) | Buy | 128.23 |
| 22 Jul 2025 | 150.00 (16.83%) | Buy | 132.75 | |
| Piper Sandler | 31 Jul 2025 | 175.00 (36.30%) | Buy | 128.23 |
| RBC Capital | 31 Jul 2025 | 144.00 (12.16%) | Buy | 128.23 |
| 02 Jun 2025 | 145.00 (12.94%) | Buy | 124.56 | |
| Stifel | 31 Jul 2025 | 174.00 (35.52%) | Buy | 128.23 |
| Wedbush | 31 Jul 2025 | 141.00 (9.82%) | Buy | 128.23 |
| Truist Securities | 21 Jul 2025 | 163.00 (26.96%) | Buy | 131.83 |
| Goldman Sachs | 10 Jul 2025 | 182.00 (41.76%) | Buy | 134.92 |
| UBS | 09 Jul 2025 | 174.00 (35.52%) | Buy | 133.51 |
| Show more | ||||
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GORMAN KEVIN CHARLES | - | 125.60 | -106,322 | -13,354,043 |
| Aggregate Net Quantity | -106,322 | |||
| Aggregate Net Value ($) | -13,354,043 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 125.60 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GORMAN KEVIN CHARLES | Director | 07 Aug 2025 | Automatic sell (-) | 106,322 | 125.60 | 13,354,043 |
| GORMAN KEVIN CHARLES | Director | 07 Aug 2025 | Option execute | 106,322 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |